港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

海西新藥

133.100

-1.700-1.26%

成交量：4,100.00

成交額：55.01萬

市值：104.76億

市盈率：- -

高：135.100

開：135.000

低：132.900

收：134.800

52周最高：147.000

52周最低：97.500

股本：7,870.73萬

香港流通股本：7,870.73萬

量比：1.64

換手率：0.01%

股息：- -

股息率：- -

淨資產收益率：28.75%

總資產收益率：12.62%

市淨率：17.70

市盈率(LYR):- -

市銷率: 20.53

資料載入中...

總覽公司新聞資訊公告

海西新藥產品售價下滑：銷售費用率持續大增，賬面資金降幅不小

集採紅利要見頂？海西新藥再衝港股：主力仿製藥年底到期創新藥管線卻「斷檔」

二次衝關港交所！海西新藥業績連增，但這些隱憂得注意

4款仿製藥貢獻超90%收入，海西新藥靠集採「躺賺」，為何還急着赴港？

海西新藥擬赴港IPO！仿製藥賺錢，創新藥花

中国证券报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02637/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新藥","latestPrice":133.1,"timestamp":1763429934553,"preClose":134.8,"halted":0,"volume":4100,"delay":0,"floatShares":78707270,"shares":78707270,"eps":0,"marketStatus":"交易中","change":-1.7,"latestTime":"11-18 09:39:02","open":135,"high":135.1,"low":132.9,"amount":550145,"amplitude":0.01632,"askPrice":133.3,"askSize":50,"bidPrice":133,"bidSize":200,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1763438400000},"marketStatusCode":2,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":134.8,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":1.636826,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"12.62%","roe":"28.75%","lyrEps":0,"volumeRatio":1.636826,"shares":78707270,"dividePrice":0,"high":135.1,"amplitude":0.01632,"preClose":134.8,"low":132.9,"week52Low":97.5,"pbRate":"17.70","psRate":"20.53","week52High":147,"institutionHeld":0,"latestPrice":133.1,"committee":0.6,"eps":0,"divideRate":0,"volume":4100,"delay":0,"ttmEps":0,"open":135,"prevYearClose":86.4,"prevWeekClose":132,"prevMonthClose":119.8,"prevQuarterClose":86.4,"fiveDayClose":131.6,"twentyDayClose":104.2,"sixtyDayClose":86.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2025-11-14","current":69.713569,"percent":0.842105,"low":41.43616,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"high":76.371175,"avg":61.983096,"sd":7.689241,"marketCap":10389359640},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640}],"updateTime":1763392467971},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2561944931","title":"海西新藥產品售價下滑：銷售費用率持續大增，賬面資金降幅不小","url":"https://stock-news.laohu8.com/highlight/detail?id=2561944931","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561944931?lang=zh_tw&edition=fundamental","pubTime":"2025-08-22 10:35","pubTimestamp":1755830135,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1755759229272703273","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02637"],"gpt_icon":0},{"id":"2559011947","title":"集採紅利要見頂？海西新藥再衝港股：主力仿製藥年底到期 創新藥管線卻「斷檔」","url":"https://stock-news.laohu8.com/highlight/detail?id=2559011947","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559011947?lang=zh_tw&edition=fundamental","pubTime":"2025-08-16 14:48","pubTimestamp":1755326893,"startTime":"0","endTime":"0","summary":"【集采红利要见顶？海西新药再冲港股：主力仿制药年底到期 创新药管线却“断档”】近日，福建海西新药创制股份有限公司向港交所更新招股书，再度发起港股上市冲击。这家名称凸显“新药”属性的药企，核心业绩却高度依赖仿制药业务——2022至2024年，仿制药收入占比连续三年超90%，其中集采中标品种贡献近六成营收，成为驱动业绩增长的核心引擎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202508163486020669.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202508163486020669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["HSCEI","YANG","159992","BK4614","BK1574","BK1161","07226","HSTECH","02637"],"gpt_icon":1},{"id":"2559930559","title":"二次衝關港交所！海西新藥業績連增，但這些隱憂得注意","url":"https://stock-news.laohu8.com/highlight/detail?id=2559930559","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559930559?lang=zh_tw&edition=fundamental","pubTime":"2025-08-14 15:20","pubTimestamp":1755156056,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814152517a6e58626&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814152517a6e58626&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637"],"gpt_icon":0},{"id":"2559933319","title":"4款仿製藥貢獻超90%收入，海西新藥靠集採「躺賺」，為何還急着赴港？","url":"https://stock-news.laohu8.com/highlight/detail?id=2559933319","media":"TMTPost","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559933319?lang=zh_tw&edition=fundamental","pubTime":"2025-08-14 09:34","pubTimestamp":1755135278,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tmtpost.com/7658379.html?rss=laohu8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"gpt_icon":0},{"id":"2559609072","title":"海西新藥擬赴港IPO！仿製藥賺錢，創新藥花","url":"https://stock-news.laohu8.com/highlight/detail?id=2559609072","media":"中国证券报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559609072?lang=zh_tw&edition=fundamental","pubTime":"2025-08-13 16:32","pubTimestamp":1755073920,"startTime":"0","endTime":"0","summary":"8月6日，福建海西新药创制股份有限公司（简称“海西新药”）再次向港交所递交招股书，华泰国际和招银国际担任其联席保荐人。今年1月3日，海西新药首次递交招股书。与多家创新药企业在亏损状 ...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20250813/c670340874.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250813/c670340874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02637"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":45,"code":"91000000","status":"200"}]}}